TY - JOUR
T1 - Bacteremia due to Rothia mucilaginosa after chemotherapy for myeloid malignancies
AU - Kohashi, Sumiko
AU - Mori, Takehiko
AU - Koda, Yuya
AU - Kikuchi, Taku
AU - Kato, Jun
AU - Shimizu, Takayuki
AU - Sugita, Kayoko
AU - Hasegawa, Naoki
AU - Murata, Mitsuru
AU - Okamoto, Shinichiro
PY - 2015/6/1
Y1 - 2015/6/1
N2 - The number of reported cases of bacteremia due to Rothia mucilaginosa (R. mucilaginosa), a component of the normal flora of human gastrointestinal tract mucosa, is limited. We encountered three cases of bacteremia due to R. mucilaginosa during neutropenia after chemotherapy for myeloid malignancies. Although all three patients were successfully treated with antimicrobial agents, one patient developed disseminated lesions in the lungs and soft tissue. The portal of R. mucilaginosa bacteremia is reportedly mucositis or dental disorders; however, no such complications were identified in our patients. Even in the absence of a preexisting portal, R. mucilaginosa should be recognized as a potential causative pathogen of bacteremia during neutropenic periods. Accumulations of cases and isolates are required to further elucidate the risk factors for developing R. mucilaginosa bacteremia, its clinical course, and the optimal antimicrobial treatment.
AB - The number of reported cases of bacteremia due to Rothia mucilaginosa (R. mucilaginosa), a component of the normal flora of human gastrointestinal tract mucosa, is limited. We encountered three cases of bacteremia due to R. mucilaginosa during neutropenia after chemotherapy for myeloid malignancies. Although all three patients were successfully treated with antimicrobial agents, one patient developed disseminated lesions in the lungs and soft tissue. The portal of R. mucilaginosa bacteremia is reportedly mucositis or dental disorders; however, no such complications were identified in our patients. Even in the absence of a preexisting portal, R. mucilaginosa should be recognized as a potential causative pathogen of bacteremia during neutropenic periods. Accumulations of cases and isolates are required to further elucidate the risk factors for developing R. mucilaginosa bacteremia, its clinical course, and the optimal antimicrobial treatment.
UR - http://www.scopus.com/inward/record.url?scp=84946107138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946107138&partnerID=8YFLogxK
U2 - 10.11406/rinketsu.56.687
DO - 10.11406/rinketsu.56.687
M3 - Article
C2 - 26256880
AN - SCOPUS:84946107138
SN - 0485-1439
VL - 56
SP - 687
EP - 691
JO - [Rinshō ketsueki] The Japanese journal of clinical hematology
JF - [Rinshō ketsueki] The Japanese journal of clinical hematology
IS - 6
ER -